Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose
Journal of Gastroenterology and Hepatology, 06/08/2012Sharma P et al.
Lactulose is effective for primary prevention of overt hepatic encephalopathy in patients with cirrhosis.
Consecutive cirrhotic patients who never had an episode of overt HE were randomized to receive lactulose (Gp-L) or no lactulose (Gp-NL).
All patients were assessed by psychometry [(number connection test (NCT-A and B), figure connection test if illiterate (FCT-A and B), digit symbol test (DST), serial dot test (SDT), line tracing test (LTT)] and critical flicker frequency test (CFF) at inclusion and after 3 months.
These patients were followed every month for 12 months for development of overt HE.
Of 250 patients screened, 120(48%) meeting the inclusion criteria were randomized to Gp-L(n=60) and Gp-NL(n=60).
Twenty (19%) of 105 patients followed for 12 mo developed an episode of overt HE.
Six (11%) of 55 in the lactulose (Gp-L) group and 14(28%) of 50 in the Gp-NL (p=0.02) developed overt HE.
Ten (20%) of 50 patients in Gp-NL and 5(9%) of 55 patients in Gp-L group died, p=0.16.
Number of patients with minimal hepatic encephalopathy (MHE) were comparable in two groups at baseline (Gp-L vs Gp-NL, 32:36, p=0.29).
Lactulose improved MHE in 66% of patients in Gp-L.
Taking a cutoff <38Hz sensitivity and specificity of CFF in predicting HE were 52% and 77% at baseline and 52% and 82% at 3 month of treatment.
On multivariate analysis Child's score and presence of MHE at baseline were significantly associated with development of overt HE.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.